Contemporary state and perspectives of obesity pharmacotherapy

Česká verzia

Authors: Štěpán Svačina
Authors place of work: III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN, Praha
Published in the journal: Vnitř Lék 2020; 66(8): 478-482
Category: Main Topic

Summary

The history of obesity pharmacotherapy is controversial. Many drugs are not used more due to severe side effects. Today we have four effective antiobesity drugs. The effect of some of them is comparable with bariatric sugary. Weight loss induced by bariatric surgery is culminating in the first year. The effect of incretine analogues is progressive in several years and culminating later. There are many antiobesity drugs in development. Both centrally or peripherally acting new drugs will be available soon. Even targeted therapy using antibodies will be used in obesitology soon.

Keywords:

antiobesity drugs – incretine based therapy – targeted therapy.

Zdroje

1. Svačina Š. Léčba obézního diabetika, Mladá Fronta, Praha, 2018.

2. Nissen SE, et al. Effect of Naltrexone‑Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clini‑ cal Trial. JAMA. 2016; 315(10): 990–1004.

3. Svačina Š. Obezitologie a teorie metabolického syndromu, Triton, Praha 2015.

4. Svačina Š. Antidiabetika – historie, současnost a perspektivy. Axonite, Praha, 2016.

5. Svačina Š. Semaglutid – zlom v léčbě obezity Acta medicinae, 2020; (1) 1: 37–39.

6. Astrup A, et al. Effects of liraglutide in the treatment of obesity: a randomised, double‑blind, placebo‑controlled study. Lancet. 2009; 374: 1606–1616.

7. Sangeeta P Bhat, Current Drug Targets in Obesity Pharmacotherapy – A Review Curr Drug Targets. 2017; 18(8): 983–993.

8. Gitanjali Srivastava, Caroline Apovian 2Future Pharmacotherapy for Obesity: New Anti‑obezity Drugs on the Horizon. Curr Obes Rep 2018; 7(2): 147–161.

9. Nicholas T Bello, Matthew R. Zahner Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity Tesofensin Curr Opin Investig Drugs 2009; 10(10): 1105–1116.

10. Garito T, et al. Bimagrumab improves body composition and insulin sensitivity in insulin‑resistant individuals. Diabetes Obes Metab. 2018; 20(1): 94–102.

11. Caina Li. Glutazumab, a novel long‑lasting GLP-1/anti‑GLP-1R antibody fusion protein, exerts anti‑diabetic effects through targeting dual receptor binding sites Biochem Pharmacol 2018;150: 46–53.

12. Wu AL, et al. Amelioration of type 2 diabetes by antibody‑mediated activation of fib‑ roblast growth factor receptor 1. Sci Transl Med, 2011; 3(113): 113.

13. Locke AE, et al. Genetic studies of body mass index yield new insights for obesity bio‑ logy Nature 2015; 518(7538): 197–206.

14. Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12): 2669–2701.